PMID: 18193552Jan 15, 2008Paper

Systemic autoimmune diseases

Nihon rinsho. Japanese journal of clinical medicine
Shinichi KawaiNahoko Matsumoto

Abstract

Since Hench successfully treated a patient with rheumatoid arthritis (RA) with glucocorticoid (GC) in 1948, the clinical usefulness of GC in the management of systemic autoimmune diseases has been established. However, serious adverse reactions of GC are the severe clinical problems. In addition, some of clinical evidences of GC therapy for these diseases are still controversial due to the difficulties for conducting clinical trials. In this review, we summarize the significance of GC therapy in autoimmune diseases such as RA and systemic lupus erythematosus, based upon the clinical reports for these diseases.

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.